BIT:1CVAC - NL0015436031 - Common Stock
The current stock price of 1CVAC.MI is 4.682 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 20.04 | 321.87B | ||
1ABBV.MI | ABBVIE INC | 19.56 | 314.07B | ||
AMG.DE | AMGEN INC | 12.95 | 130.47B | ||
1GILD.MI | GILEAD SCIENCES INC | 14.78 | 122.10B | ||
GIS.DE | GILEAD SCIENCES INC | 14.72 | 121.28B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 23.57 | 87.88B | ||
ARGX.BR | ARGENX SE | 85.21 | 38.64B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 21.06B | ||
IDP.DE | BIOGEN INC | 8.82 | 17.76B | ||
0QF.DE | MODERNA INC | N/A | 7.97B | ||
1MRNA.MI | MODERNA INC | N/A | 7.96B | ||
1EXAS.MI | EXACT SCIENCES CORP | N/A | 7.29B |
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG DE
Employees: 825
Phone: 49707198830
The current stock price of 1CVAC.MI is 4.682 EUR. The price decreased by -2.42% in the last trading session.
The exchange symbol of CUREVAC NV is 1CVAC and it is listed on the Euronext Milan exchange.
1CVAC.MI stock is listed on the Euronext Milan exchange.
13 analysts have analysed 1CVAC.MI and the average price target is 4.22 EUR. This implies a price decrease of -9.83% is expected in the next year compared to the current price of 4.682. Check the CUREVAC NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CUREVAC NV (1CVAC.MI) has a market capitalization of 1.05B EUR. This makes 1CVAC.MI a Small Cap stock.
CUREVAC NV (1CVAC.MI) currently has 825 employees.
The Revenue of CUREVAC NV (1CVAC.MI) is expected to decline by -84.64% in the next year. Check the estimates tab for more information on the 1CVAC.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
1CVAC.MI does not pay a dividend.
CUREVAC NV (1CVAC.MI) will report earnings on 2025-11-10.
The PE ratio for CUREVAC NV (1CVAC.MI) is 5.38. This is based on the reported non-GAAP earnings per share of 0.87 and the current share price of 4.682 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1CVAC.MI.
ChartMill assigns a technical rating of 2 / 10 to 1CVAC.MI.
ChartMill assigns a fundamental rating of 6 / 10 to 1CVAC.MI. While 1CVAC.MI has a great health rating, its profitability is only average at the moment.
Over the last trailing twelve months 1CVAC.MI reported a non-GAAP Earnings per Share(EPS) of 0.87. The EPS increased by 170.16% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 37.93% | ||
ROA | 28.11% | ||
ROE | 33.02% | ||
Debt/Equity | 0.05 |
13 analysts have analysed 1CVAC.MI and the average price target is 4.22 EUR. This implies a price decrease of -9.83% is expected in the next year compared to the current price of 4.682.
For the next year, analysts expect an EPS growth of -165.87% and a revenue growth -84.64% for 1CVAC.MI